Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2018-06-07
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension (PAH) can result in right ventricular failure and death.
Anakinra has been used in patients with left sided heart failure, and the present study looks
to determine if anakinra is safe and effective in patients with PAH. To accomplish this goal,
we plan to evaluate for exercise improvement (as assessed by cardiopulmonary exercise
testing) in 10 patients with PAH on anakinra.